



RECEIVED
NOV 18 2002
TC 1700

RECEIVED
NOV 20 2002 #16
TECH CENTER 1600/2900

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

November 12, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Guy Krippner et al.
Application No. : 10/088,282
Filed : March 15, 2002
For : ANTIVIRAL AGENTS

RECEIVED
NOV 21 2002
TECH CENTER 1600/2900

Docket No. : 150070.402USPC
Date : November 12, 2002

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Guy Krippner et al.
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507

Enclosures:

Postcard
Form PTO/SB/21
Forms PTO-1449
Cited References (7)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\JASONA\334201_1.DOC



Sheet 1 of 1

RECEIVED
NOV 18 2002
TC 1700

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
150070.402USPCAPPLICATION NO.
10/088,282APPLICANT
Guy Krippner et al.FILING DATE
March 15, 2002

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						RECEIVED
	AC						NOV 21 2002
	AD						
	AE						TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	WO 99/64036	12/16/99	WIPO		X
	AG	WO 00/55149	09/21/00	WIPO		X
	AH					
	AI					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AJ		Matrosovich, M.N., "Towards the Development of Antimicrobial Drugs Acting by Inhibition of Pathogen Attachment to Host Cells: A Need for Polyvalency," <i>Fed. of European Biochem. Soc.</i> , 252(1,2):1-4, 1989.
AK		Spaltenstein, A. et al., "Polyacrylamides Bearing Pendant a-Sialoside Groups Strongly Inhibit a Agglutination of Erythrocytes by Influenza Virus," <i>J. Am. Chem. Soc.</i> , Vol. 113, pp. 686-687, 1991.
AL		Glick, G. et al., "Ligand Recognition by Influenza Virus. The Binding of Bivalent Sialosides," <i>J. of Bio. Chem.</i> , 266(35):23660-23669, December 15, 1991.
AM		Kramer, R. et al., "Spanning Binding Sites on Allosteric Proteins with Polymer-Linked Ligand Dimers," <i>Nature</i> , Vol. 395, pp. 710-713, October 15, 1998.
AN		Mammen, M. et al., "Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors," <i>Angew. Chem. Int'l Ed.</i> , Vol. 37, pp. 2754-2794, 1998.
AO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).